Background: Interventional radiotherapy (brachytherapy; IRT) reemerged in the last decades as a potentially useful tool in head and neck oncology after a set of clear technical improvements were developed. Methods: Sixty-one high dose ratio (HDR) IRT treatments were recommended and performed on 58 patients. We classified the cases into four relatively homogeneous groups based on the clinical needs that led to the recommended IRT. Also, we separately evaluated primary and recurrent cases. Results: Disease-specific survival was significantly different among the four treatment groups. The group with the best prognosis was the cohort treated locally by exclusive interstitial IRT for resectable midface malignancies (2-year relapse-free survival = 82%, disease-specific survival = 89%). Conclusion: HDR IRT is a valuable tool in well-defined clinical situations and, in particular, in recurrences. In midface malignancies, it could become the preferred primary treatment.

HDR interventional radiotherapy (brachytherapy) in the treatment of primary and recurrent head and neck malignancies / Bussu, F.; Tagliaferri, L.; Mattiucci, G.; Parrilla, C.; Rizzo, D.; Gambacorta, M. A.; Lancellotta, V.; Autorino, R.; Fonnesu, C.; Kihlgren, C.; Galli, J.; Paludetti, G.; Kovacs, G.; Valentini, V.. - In: HEAD & NECK. - ISSN 1043-3074. - 41:6(2019), pp. 1667-1675. [10.1002/hed.25646]

HDR interventional radiotherapy (brachytherapy) in the treatment of primary and recurrent head and neck malignancies

Bussu F.
;
Rizzo D.;Kihlgren C.;Galli J.;
2019

Abstract

Background: Interventional radiotherapy (brachytherapy; IRT) reemerged in the last decades as a potentially useful tool in head and neck oncology after a set of clear technical improvements were developed. Methods: Sixty-one high dose ratio (HDR) IRT treatments were recommended and performed on 58 patients. We classified the cases into four relatively homogeneous groups based on the clinical needs that led to the recommended IRT. Also, we separately evaluated primary and recurrent cases. Results: Disease-specific survival was significantly different among the four treatment groups. The group with the best prognosis was the cohort treated locally by exclusive interstitial IRT for resectable midface malignancies (2-year relapse-free survival = 82%, disease-specific survival = 89%). Conclusion: HDR IRT is a valuable tool in well-defined clinical situations and, in particular, in recurrences. In midface malignancies, it could become the preferred primary treatment.
HDR interventional radiotherapy (brachytherapy) in the treatment of primary and recurrent head and neck malignancies / Bussu, F.; Tagliaferri, L.; Mattiucci, G.; Parrilla, C.; Rizzo, D.; Gambacorta, M. A.; Lancellotta, V.; Autorino, R.; Fonnesu, C.; Kihlgren, C.; Galli, J.; Paludetti, G.; Kovacs, G.; Valentini, V.. - In: HEAD & NECK. - ISSN 1043-3074. - 41:6(2019), pp. 1667-1675. [10.1002/hed.25646]
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: http://hdl.handle.net/11388/231853
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 14
  • ???jsp.display-item.citation.isi??? 12
social impact